Alzheimer's Disease Research

At Lilly, we want to continue developing and making medicines to meet the needs of people with Alzheimer’s disease and those that care for them.

Alzheimer’s is the most common cause of dementia. It involves a build-up of protein in the brain which forms amyloid plaques and tau tangles. These proteins damage the brain and stop it from working the way it should.

Through clinical research we are looking to find potential medicines that may help treat or slow down the development of Alzheimer’s disease and other types of dementia. By taking part in a clinical research study, you can help to make a difference. Click here to view Alzheimer’s disease trials.

Two people joyfully embracing while standing on a porch. Both have grey hair, one person is wearing a purple top and the other person is wearing a grey shirt.

Participating in a Trial

It can be overwhelming to think about participating in a clinical trial, and you might have a lot of questions. In this section, we give you some information about what to expect before, during and after a trial. By using this information, and talking to your doctor, research team and loved ones it may help you decide if a clinical research study is the right path.

Graphic of 3 puzzle pieces.

Lilly Trial Connect

Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Trial

Browse our list of current clinical trials to see if one of the trials is right for you, or sign up to receive Lilly Trials Alerts when new trials are listed or begin enrolling near you.

Conditions: Alzheimer's disease
Trial Name
TRAILRUNNER-ALZ 1
Drugs: Remternetug (LY3372993)
Age
60 - 85 years
Phase
III
Conditions: Alzheimer's disease
Drugs: donanemab
Age
60 - 85 years
Phase
III
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 3
Drugs: Donanemab, LY3002813
Age
65 - 80 years
Phase
III
Conditions: Alzheimer's disease
Drugs: donanemab
Age
60 - 85 years
Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Not the right fit? Sign up to receive Lilly Trial Alerts to find out about new trials.

Alzheimer's Resources